Opportunity ID: 359096
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | HT942525PRCRPCTA |
| Funding Opportunity Title: | DOD Peer Reviewed Cancer, Clinical Trial Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 8 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | May 22, 2025 |
| Last Updated Date: | Jun 06, 2025 |
| Original Closing Date for Applications: | Sep 25, 2025 |
| Current Closing Date for Applications: | Sep 25, 2025 |
| Archive Date: | Oct 25, 2025 |
| Estimated Total Program Funding: | $33,600,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: |
Summary: The fiscal year 2025 (FY25) Peer Reviewed Cancer Research Program (PRCRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of cancer within at least one of the FY25 PRCRP topic areas. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) that evaluate the effects of interventions or inform the design of more advanced trials to large-scale trials (up to phase III) to determine efficacy in relevant patient populations. Distinctive Features: • Applications to this award mechanism must include a clinical trial. • Projects can range from phase 0 to phase III. • If an Investigational New Drug Application (IND) or an Investigational Device Exemption (IDE) is required, the application must be submitted to the FDA prior to the FY25 PRCRP Clinical Trial Award application submission deadline (this includes clinical trials requesting exception from informed consent under Code of Federal Regulations, Title 21, Part 50.24 (21 CFR 50.24). • Animal studies are NOT allowed under this award mechanism. All preclinical work must be completed prior to the award start date. Funding Details: (New for FY25) Funding limits are now listed as total cost limits, which is the combination of both direct and indirect costs. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk
Phone: 301-682-5507 Email: help@eBRAP.org Email:help@eBRAP.org |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
| Modified the IND requirement in two sections of the PA, under distinctive features and Attachment 9: Regulatory Strategy. | Jun 06, 2025 | |
| May 22, 2025 |
DISPLAYING: Synopsis 2
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | HT942525PRCRPCTA |
| Funding Opportunity Title: | DOD Peer Reviewed Cancer, Clinical Trial Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 8 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | May 22, 2025 |
| Last Updated Date: | Jun 06, 2025 |
| Original Closing Date for Applications: | Sep 25, 2025 |
| Current Closing Date for Applications: | Sep 25, 2025 |
| Archive Date: | Oct 25, 2025 |
| Estimated Total Program Funding: | $33,600,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: |
Summary: The fiscal year 2025 (FY25) Peer Reviewed Cancer Research Program (PRCRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of cancer within at least one of the FY25 PRCRP topic areas. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) that evaluate the effects of interventions or inform the design of more advanced trials to large-scale trials (up to phase III) to determine efficacy in relevant patient populations. Distinctive Features: • Applications to this award mechanism must include a clinical trial. • Projects can range from phase 0 to phase III. • If an Investigational New Drug Application (IND) or an Investigational Device Exemption (IDE) is required, the application must be submitted to the FDA prior to the FY25 PRCRP Clinical Trial Award application submission deadline (this includes clinical trials requesting exception from informed consent under Code of Federal Regulations, Title 21, Part 50.24 (21 CFR 50.24). • Animal studies are NOT allowed under this award mechanism. All preclinical work must be completed prior to the award start date. Funding Details: (New for FY25) Funding limits are now listed as total cost limits, which is the combination of both direct and indirect costs. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk
Phone: 301-682-5507 Email: help@eBRAP.org Email:help@eBRAP.org |
DISPLAYING: Synopsis 1
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | HT942525PRCRPCTA |
| Funding Opportunity Title: | DOD Peer Reviewed Cancer, Clinical Trial Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 8 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | May 22, 2025 |
| Last Updated Date: | May 22, 2025 |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Sep 25, 2025 |
| Archive Date: | Oct 25, 2025 |
| Estimated Total Program Funding: | $33,600,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: |
Summary: The fiscal year 2025 (FY25) Peer Reviewed Cancer Research Program (PRCRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of cancer within at least one of the FY25 PRCRP topic areas. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) that evaluate the effects of interventions or inform the design of more advanced trials to large-scale trials (up to phase III) to determine efficacy in relevant patient populations. Distinctive Features: • Applications to this award mechanism must include a clinical trial. • Projects can range from phase 0 to phase III. • If an Investigational New Drug Application (IND) or an Investigational Device Exemption (IDE) is required, an active IND or IDE with a determination of safe to proceed must be submitted by the PRCRP Clinical Trial Award application submission deadline (this includes clinical trials requesting exception from informed consent under Code of Federal Regulations, Title 21, Part 50.24 (21 CFR 50.24). • Animal studies are NOT allowed under this award mechanism. All preclinical work must be completed prior to the award start date. Funding Details: (New for FY25) Funding limits are now listed as total cost limits, which is the combination of both direct and indirect costs. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk
Phone: 301-682-5507 Email: help@eBRAP.org Email:help@eBRAP.org |
Related Documents
Packages
| Agency Contact Information: | CDMRP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org Email: help@eBRAP.org |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 12.420 | PKG00290858 | May 22, 2025 | Sep 25, 2025 | View |
Package 1
Mandatory forms
Optional forms
Share This Post, Choose Your Platform!
About the Author: osnqt
